Oxonica Diagnostics

NANOPLEX™ biomarker detection

These silica-coated, surface enhanced Raman scattering (SERS)-active metal nanoparticles allow robust, ultrasensitive, highly-multiplexed biomarker quantitation in any biological matrix, including whole blood.

Click here to view NANOPLEX biomarker formation animation

The NANOPLEX™ technology, comprising portable readers, software, nanoparticles, and conjugation protocols, allows high-performance, multiplexed assays to be developed for immunodiagnostics, molecular diagnostics, and proteomics, in a wide range of formats, from disposable, rapid lateral flow tests to highly innovative assay formats for near patient and hospital lab testing , to high-throughput multi-well screens.

Advantages to the technology include:
  • High-level multiplexing and simultaneous internal calibration
  • Minimal, interference from highly-coloured and/or scattering samples such as blood or fixed tissue, as well as from consumable materials such as polypropylene, nitrocellulose, etc. through near-infrared excitation and detection
  • Environment-insensitive signal generation, and simple biofunctionalization through a silica (glass) coating

Together, these benefits translate to unprecedented capabilities for biomarker quantitation, with the ability to support the implementation of the next generation of ultra-sensitive, multiplexed biomarkers, covering a wide range of areas, from infectious disease, cardiac and cancer diagnostics to food testing for pathogens and animal health.

Oxonica Healthcare is based in our Mountain View facility, California, USA.

Publications on the Nanoplex™ biotag Technology